(Q48363369)

English

PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.

scientific article published on 25 March 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Ai Maeda

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Katsuhiko Shimizu

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Yuji Nojima

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Shinsuke Saisho

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Masao Nakata

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

publication date

25 March 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

66

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

865-876

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Programmed death ligand-1 expression in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

The discovery of receptor tyrosine kinases: targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Feedback regulation of EGFR signalling: decision making by early and delayed loops.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

The PD-1-PD-L pathway in immunological tolerance

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Inhibitory B7-family molecules in the tumour microenvironment

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Blood vessel invasion in resected non small cell lung carcinomas is predictive of metastatic occurrence

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-1986-Y

21 January 2018

Identifiers

10.1007/S00262-017-1986-Y

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28341875%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48363369&oldid=2209380497"